Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors
Conditions: TNBC – Triple-Negative Breast Cancer; Head and Neck Squamous Cell Carcinoma; Squamous Cell Carcinoma of Anal Canal; Uveal Melanoma; Glioblastoma; Colorectal Cancer; Chordoma; Squamous Cell Carcinoma of the Lung; KRAS G12D; KRAS G13D; EGFR Amplification; Epithelial Ovarian Cancer; Hepatocellular Carcinoma; Anaplastic Thyroid Cancer; Pancreas Cancer
Interventions: Drug: BCA101; Drug: Pembrolizumab
Sponsor: Bicara Therapeutics
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.